Any current/future new fundraising through debt or equity?

No new plant CAPEX planned; only annual maintenance CAPEX of Rs. 40-50 crores. No new long-term borrowing planned; current debt is being repaid at Rs. 40-50 crores per year. Peak debt levels referred to are current peak; no additional long-term debt is on the cards. Management is monitoring working capital needs and revenue growth that may influence debt requirements, but currently, no new debt approval. No mention of any new equity fundraising plans during the discussed period. Focus remains on organic growth and managing existing assets/liabilities without fresh capital infusion.

Any current/future capex/capital investment/strategic investment?

Currently, no new plants are planned. Maintenance CAPEX is ongoing, approximately Rs. 40-50 crores annually due to existing large plants. No new CAPEX plans have been approved or are currently on the cards. The company focuses on maintenance and sustaining current operations rather than expansion CAPEX in the near term. As revenue increases, there might be future requirements, but nothing specific is planned now.

Future growth expectations in sales/revenue/volumes?

Revenue guidance for FY'27 is approximately Rs. 2,200 crores; for FY'28, around Rs. 2,400 crores. Vanillin volume guidance for FY'27 is 4,000 metric tons, indicating a growth of about 50%-60% from FY'26. Blend business projected to grow by 20%-25% over FY'26, targeting around Rs. 1,350 crores in FY'27 from Rs. 1,000 crores. Vitafor (animal feed segment) expected to grow 40%-50% in FY'27 from current top-line of €12-13 million to €17-18 million. Ethyl Vanillin production to commence shortly, targeting approximately 300 tons by March next quarter, adding to volumes. Overall, a combined

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue guidance for FY'27 is approximately Rs. 2,200 crores, growing to Rs. 2,400 crores in FY'28. Vanillin sales are expected to grow significantly with a volume target of about 4,000 metric tons in FY'27. Blend business is projected to grow around 25% over FY'26, contributing to overall revenue growth. Gross margins are expected to improve by 1%-2% to reach approximately 46%-47% in FY'27, aided by higher Vanillin realizations and Blend growth. EBITDA margins are anticipated to increase to a range of 12%-14% driven by volume growth and improved realizations. Cost pressures from Straights bus

Current/ Expected Orderbook/ Pending Orders?

The transcripts provided do not explicitly mention the current or expected order book or pending orders for Camlin Fine Sciences Limited. However, the company indicates strong demand growth, especially in blends and Vanillin segments. They expect Vanillin sales to increase to about 4,000 tons in FY'27, up from 2,300-2,400 tons, reflecting optimism about order flow. Blends segment is projected to grow 25% over FY'26. The company is actively working on expanding market access, including launching new products like ethyl Vanillin and expanding in markets like the US, Europe, Brazil, and India. Th

IN US

Sale is live|00:00:00left today

Camlin Fine Sciences LtdQ4 FY27Chemicals & Petrochemicals

Camlin Fine Sciences Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹138P/E: 1014.3Market Cap: ₹2.4K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Revenue guidance for FY'27 is approximately Rs. 2,200 crores; for FY'28, around Rs. 2,400 crores.
→Vanillin volume guidance for FY'27 is 4,000 metric tons, indicating a growth of about 50%-60% from FY'26.
→Blend business projected to grow by 20%-25% over FY'26, targeting around Rs. 1,350 crores in FY'27 from Rs. 1,000 crores.
→Vitafor (animal feed segment) expected to grow 40%-50% in FY'27 from current top-line of €12-13 million to €17-18 million.
→Ethyl Vanillin production to commence shortly, targeting approximately 300 tons by March next quarter, adding to volumes.
→Overall, a combined growth in Vanillin and Blend segments expected to drive revenue and margin improvement.

Margin guidance

Category 2

→Revenue guidance for FY'27 is approximately Rs. 2,200 crores, growing to Rs. 2,400 crores in FY'28.
→Vanillin sales are expected to grow significantly with a volume target of about 4,000 metric tons in FY'27.
→Blend business is projected to grow around 25% over FY'26, contributing to overall revenue growth.
→Gross margins are expected to improve by 1%-2% to reach approximately 46%-47% in FY'27, aided by higher Vanillin realizations and Blend growth.
→EBITDA margins are anticipated to increase to a range of 12%-14% driven by volume growth and improved realizations.
→Cost pressures from Straights business with margin compression are being offset by gains in Vanillin and Blends.
→Operational improvements expected from cessation of cash bleed in European and China operations post-liquidation.
→No major CAPEX planned; focus remains on controlled growth with maintenance CAPEX of Rs. 40-50 crores annually.

3 more insights locked — sign up free to unlock

Fundraise plans

→No new plant CAPEX planned; only annual maintenance CAPEX of Rs. 40-50 crores.
→No new long-term borrowing planned; current debt is being repaid at Rs. 40-50 crores per year.
→Peak debt levels referred to are current peak; no additional long-term debt is on the cards.
→Management is monitoring working capital needs and revenue growth that may influence debt requirements, but currently, no new debt approval.
→No mention of any new equity fundraising plans during the discussed period.
→Focus remains on organic growth and managing existing assets/liabilities without fresh capital infusion.

Order book

→The transcripts provided do not explicitly mention the current or expected order book or pending orders for Camlin Fine Sciences Limited.
→However, the company indicates strong demand growth, especially in blends and Vanillin segments.
→They expect Vanillin sales to increase to about 4,000 tons in FY'27, up from 2,300-2,400 tons, reflecting optimism about order flow.
→Blends segment is projected to grow 25% over FY'26.
→The company is actively working on expanding market access, including launching new products like ethyl Vanillin and expanding in markets like the US, Europe, Brazil, and India.
→The recent acquisition of Vinpai is expected to contribute to increasing sales and margins as volume builds.
→There is also reference to managing channel inventory in Vanillin to optimize pricing and sales timing.
→Maintenance CAPEX is around Rs. 40-50 crores, with no new plants or major CAPEX planned, implying demand absorption will rely on existing capacities.

Capex plans

→Currently, no new plants are planned.
→Maintenance CAPEX is ongoing, approximately Rs. 40-50 crores annually due to existing large plants.
→No new CAPEX plans have been approved or are currently on the cards.
→The company focuses on maintenance and sustaining current operations rather than expansion CAPEX in the near term.
→As revenue increases, there might be future requirements, but nothing specific is planned now.

How does Camlin Fine Sciences Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Camlin Fine Sciences Ltd

Rev 2Mar 2

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Camlin Fine Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio